Matches in SemOpenAlex for { <https://semopenalex.org/work/W162692105> ?p ?o ?g. }
Showing items 1 to 86 of
86
with 100 items per page.
- W162692105 endingPage "266" @default.
- W162692105 startingPage "262" @default.
- W162692105 abstract "PurposeTo assess the efficacy of nedocromil sodium 2% eye drops and emedastine difumarate 0.05% eye drops in controlling the ocular allergic reaction induced by conjunctival allergen challenge (CAC). MethodsThirty subjects with a personal history of allergic conjunctivitis were enrolled (first visit). At the second visit each subject randomly received emedastine 0.05% or nedocromil 2% in one eye and placebo in the other eye. Five minutes after the medication the offending allergen was instilled in both eyes. Ocular redness and itching were evaluated according to a standardized scoring system at 3, 10 and 20-minute intervals after instillation of the allergen. After one week (third visit) the whole procedure was repeated using the placebo in the eye used as control during second visit and one of the trial drug that was not used at second visit in the other eye (either emedastine or nedocromil). ResultsEmedastine 0.05% and nedocromil 2% eye drops were more effective than placebo in controlling ocular redness and itching (p<0.01). Emedastine was more effective (p<0.01) than nedocromil in alleviating redness and itching 3 and 10 minutes after application of the allergen. ConclusionsEmedastine 0.05% appeared superior to nedocromil 2% in producing immediate relief when subjects with allergic conjunctivitis were exposed to the offending allergen." @default.
- W162692105 created "2016-06-24" @default.
- W162692105 creator A5002447831 @default.
- W162692105 creator A5019467636 @default.
- W162692105 creator A5032531991 @default.
- W162692105 creator A5050653687 @default.
- W162692105 creator A5057233562 @default.
- W162692105 creator A5066653562 @default.
- W162692105 date "2002-07-01" @default.
- W162692105 modified "2023-10-14" @default.
- W162692105 title "Comparison of Emedastine 0.05% or Nedocromil Sodium 2% Eye Drops and Placebo in Controlling Local Reactions in Subjects with Allergic Conjunctivitis" @default.
- W162692105 cites W1979415789 @default.
- W162692105 cites W2040720976 @default.
- W162692105 cites W2041063903 @default.
- W162692105 cites W2084383274 @default.
- W162692105 cites W2096785196 @default.
- W162692105 cites W2135412234 @default.
- W162692105 cites W2164020272 @default.
- W162692105 cites W2165254265 @default.
- W162692105 cites W62181560 @default.
- W162692105 doi "https://doi.org/10.1177/112067210201200402" @default.
- W162692105 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12219994" @default.
- W162692105 hasPublicationYear "2002" @default.
- W162692105 type Work @default.
- W162692105 sameAs 162692105 @default.
- W162692105 citedByCount "9" @default.
- W162692105 countsByYear W1626921052013 @default.
- W162692105 countsByYear W1626921052014 @default.
- W162692105 countsByYear W1626921052015 @default.
- W162692105 crossrefType "journal-article" @default.
- W162692105 hasAuthorship W162692105A5002447831 @default.
- W162692105 hasAuthorship W162692105A5019467636 @default.
- W162692105 hasAuthorship W162692105A5032531991 @default.
- W162692105 hasAuthorship W162692105A5050653687 @default.
- W162692105 hasAuthorship W162692105A5057233562 @default.
- W162692105 hasAuthorship W162692105A5066653562 @default.
- W162692105 hasConcept C118487528 @default.
- W162692105 hasConcept C142724271 @default.
- W162692105 hasConcept C16005928 @default.
- W162692105 hasConcept C203014093 @default.
- W162692105 hasConcept C204787440 @default.
- W162692105 hasConcept C207480886 @default.
- W162692105 hasConcept C27081682 @default.
- W162692105 hasConcept C2776002719 @default.
- W162692105 hasConcept C2777625524 @default.
- W162692105 hasConcept C2779923671 @default.
- W162692105 hasConcept C2780870513 @default.
- W162692105 hasConcept C2910070530 @default.
- W162692105 hasConcept C42219234 @default.
- W162692105 hasConcept C71924100 @default.
- W162692105 hasConceptScore W162692105C118487528 @default.
- W162692105 hasConceptScore W162692105C142724271 @default.
- W162692105 hasConceptScore W162692105C16005928 @default.
- W162692105 hasConceptScore W162692105C203014093 @default.
- W162692105 hasConceptScore W162692105C204787440 @default.
- W162692105 hasConceptScore W162692105C207480886 @default.
- W162692105 hasConceptScore W162692105C27081682 @default.
- W162692105 hasConceptScore W162692105C2776002719 @default.
- W162692105 hasConceptScore W162692105C2777625524 @default.
- W162692105 hasConceptScore W162692105C2779923671 @default.
- W162692105 hasConceptScore W162692105C2780870513 @default.
- W162692105 hasConceptScore W162692105C2910070530 @default.
- W162692105 hasConceptScore W162692105C42219234 @default.
- W162692105 hasConceptScore W162692105C71924100 @default.
- W162692105 hasIssue "4" @default.
- W162692105 hasLocation W1626921051 @default.
- W162692105 hasLocation W1626921052 @default.
- W162692105 hasOpenAccess W162692105 @default.
- W162692105 hasPrimaryLocation W1626921051 @default.
- W162692105 hasRelatedWork W127444855 @default.
- W162692105 hasRelatedWork W1990250264 @default.
- W162692105 hasRelatedWork W2010385231 @default.
- W162692105 hasRelatedWork W2011872206 @default.
- W162692105 hasRelatedWork W2030209842 @default.
- W162692105 hasRelatedWork W2059066094 @default.
- W162692105 hasRelatedWork W2064689285 @default.
- W162692105 hasRelatedWork W2108300001 @default.
- W162692105 hasRelatedWork W2416450269 @default.
- W162692105 hasRelatedWork W2492702463 @default.
- W162692105 hasVolume "12" @default.
- W162692105 isParatext "false" @default.
- W162692105 isRetracted "false" @default.
- W162692105 magId "162692105" @default.
- W162692105 workType "article" @default.